Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO's share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of C$11.11 and traded as low as C$5.39. Aptose Biosciences shares last traded at C$5.46, with a volume of 708 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Alliance Global Partners raised shares of Aptose Biosciences to a "strong-buy" rating in a research note on Thursday, February 27th.
Get Our Latest Analysis on APS
Aptose Biosciences Price Performance
The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37. The business's 50-day moving average is C$7.03 and its two-hundred day moving average is C$10.92. The company has a market capitalization of C$219.60 million, a P/E ratio of -1.02 and a beta of 1.36.
About Aptose Biosciences
(
Get Free Report)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
Before you consider Aptose Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aptose Biosciences wasn't on the list.
While Aptose Biosciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
